Ricky Martin, HRS (Chair)

Nadia Shivji-Brown, Public Health England (PHE)

Andrew Carr, Charles River Laboratories (CRL)

Renos Savva, Birkbeck, University of London


Recognise this? It’s a common sight in many research facilities across the world: container after container filled with important biological samples. It may mean it’s time to upgrade from containers to a better, long-term solution.

During our careers, the opportunity to work on something genuinely ground-breaking, something pioneering that raises the bar, is extremely rare. In October, the Kao Data team was contacted by NVIDIA regarding their Cambridge-1 project. As soon as we saw the plans for the UK’s most powerful supercomputer, we were hooked.

Once again, One Nucleus held a really useful and informative session whereby an intimate group of attendees gathered to discuss thought-provoking questions posed by the One Nucleus community.  Discussions each take place in individual breakout groups, but so the key take-aways can be disseminated more widely, this wrap-up serves to provide an overview of all discussions.  Therefore, regardless of the breakout group individuals were in, the insights are shared amongst all.

Our My Question is….Networking Lunches are gaining momentum now and one might say an adept way of keeping in touch as we come to the end of a cold, locked down January.  Once again, our network was primed with a variety of questions across different topics that they were keen to debate.  Over 30 delegates joined our virtual networking session looking to meet and catch up with others informally and for perhaps a learning experience too.  Five breakout rooms and five questions later, here is what came out of the discussions:

How will the loss of in-person laboratory teaching impact job prospects?

As a follow up to our recent poll asking if the current undergraduates who are losing in-person laboratory teaching will be disadvantaged in securing future jobs.

The results can be summarised as:

Our second ‘My Question is…Networking Lunch’ saw another round of enticing questions submitted by the One Nucleus community.  Six questions were chosen from those submitted and then the individuals who submitted the questions hosted a small breakout group to discuss that question.  40 delegates joined the virtual networking meeting on Monday 30 November 2020. 

The discussions were an opportunity for attendees to engage with others in their group, whilst sharing their expertise or perhaps using it to learn more about the topic being debated.

The JP Morgan (JPM) Conference, a staple of the life science sector and one of biotech’s biggest conferences, will be going virtual in January 2021 which has become something of a norm for events under Covid-19.  One Nucleus has also been running its own BioWednesdays virtually and our first session of 2021 drew together a panel of experienced JPM Conference attendees to look at what to expect from a virtual JPM Week and what they would like to see for the future.

The lunchtime panel discussion at Genesis Digital 2020 will discuss the question ‘Has Covid-19 make it easier or harder to create a biotech company?' In advance of this, science writer Dr Clare Sansom caught up with one of the panellists, Dr Anne Lane. Dr Lane is CEO of UCL’s commercialisation company, UCLB.

Q. How has COVID-19 changed the way that UCLB operates? What has been hardest, and has anything been easier?